Condition: Squamous Cell Carcinoma of Head and Neck · Sinus Cancer · Nasal Cavity Cancer · Sponsor: Memorial Sloan Kettering Cancer Center
The purpose of this study to find out whether sacituzumab govitecan in combination with cetuximab is an effective and safe treatment approach for people with recurrent and/or metastatic head and neck squamous cell cancer (HNSCC).
This description comes directly from the study's public registry record.
Winston Wong, MD · 646-608-4245 · wongw3@mskcc.org
Loren Michel, MD · 848-225-6113 · michell@mskcc.org
Always discuss trial participation with your own doctor first.
| Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) | Basking Ridge, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Monmouth (Limited Protocol Activities) | Middletown, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Bergen (Limited Protocol Activities) | Montvale, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities) | Commack, New York, United States | Recruiting |
| Memorial Sloan Kettering Westchester (All Protocol Activities) | Harrison, New York, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center (All Protocol Activites) | New York, New York, United States | Recruiting |
| Memorial Sloan Kettering Nassau (Limited Protocol Activities) | Uniondale, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07063212